DIMETHYL 3-(BENZYLOXY)-4-OXO-4H-PYRAN-2,5-DICARBOXYLATE, 95.0%, 25g

Ravoxertinib, 99.75%, 10mg

tert-Butyl hexahydro-1H-pyrrolo[3,4-c]pyridine-5(6H)-carboxylate hydrochloride, 95.0%, 2g

Vial de reacción con brida plana, cilíndrico, graduado, con camisa protectora, pieza de conexión GL, DN 100, 4000 ml, 190 mm, 1 pieza

(3R,4S)-3-(BOC-AMINO)-4-FLUORO-PYRROLIDINE, 95.0%, 250mg

Puerta de fundición de gel PROfessional I, 1 par

3,4,5-Trimethoxyphenylacetic acid, 95.0%, 5g

4-isopropyl-1-phenyl-1,6-dihydro-7H-pyrazolo[3,4-d]pyridazin-7-one, 95.0%, 500mg

2-Chloro-3-methoxy-6-nitroaniline, 98%, 250mg

2-Bromo-4-iodo-1-(trifluoromethoxy)benzene, 95.0%, 5g

4-(1,3-Thiazol-2-yl)benzaldehyde, 95.0%, 100g

4-Fluoro-3-nitro-benzyl alcohol, 95.0%, 25g

(9H-fluoren-9-yl)methyl (S)-(1-(4-(tert-butoxy)phenyl)-3-hydroxypropan-2-yl)carbamate, 95+%, 5g